Skip Navigation

Cardiovascular Research 2002 53(4):806-821; doi:10.1016/S0008-6363(01)00493-X
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bueno, O. F
Right arrow Articles by De Windt, L. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bueno, O. F
Right arrow Articles by De Windt, L. J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Calcineurin and hypertrophic heart disease: novel insights and remaining questions

Orlando F Buenoa, Eva van Rooijb, Jeffery D Molkentina, Pieter A Doevendansb and Leon J De Windtb,*

aDivision of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati OH, USA
bDepartment of Cardiology, Cardiovascular Research Institute Maastricht, University Hospital Maastricht, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands

leon.dewindt{at}cardio.unimaas.nl

* Corresponding author. Tel.: +31-43-388-2949; fax: +31-43-387-5104

In the past 2 years, an emerging body of research has focused on a novel transcriptional pathway involved in the cardiac hypertrophic response. Ever since its introduction, the significance of the calcineurin–NFAT module has been subject of controversy. The aim of this review is to provide both an update on the current status of knowledge and discuss the remaining issues regarding the involvement of calcineurin in hypertrophic heart disease. To this end, the molecular biology of calcineurin and its direct downstream transcriptional effector NFAT are discussed in the context of the genetic studies that established the existence of this signaling paradigm in the heart. The pharmacological mode-of-action and specificity of the calcineurin inhibitors cyclosporine A (CsA) and FK506 is dicussed, as well as their inherent limitations to study the biology of calcineurin. A critical interpretation is given on studies aimed at analyzing the role of calcineurin in cardiac hypertrophy using systemic immunosuppression. To eliminate the controversy surrounding CsA/FK506 usage, recent studies employed genetic inhibitory strategies for calcineurin, which confirm the pivotal role for this signal transduction pathway in the ventricular hypertrophy response. Finally, unresolved issues concerning the role of calcineurin in cardiac pathobiology are discussed based upon the information available, including its controversial role in cardiomyocyte viability, the reciprocal relationship between myocyte Ca2+ homeostasis and calcineurin activity and the relative importance of calcineurin in relation to other hypertrophic signaling cascades.

KEYWORDS Apoptosis; Calcium (cellular); Cardiomyopathy; Gene expression; Heart failure; Hypertrophy; Signal transduction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
A. M. Prasad and G. Inesi
Effects of thapsigargin and phenylephrine on calcineurin and protein kinase C signaling functions in cardiac myocytes
Am J Physiol Cell Physiol, May 1, 2009; 296(5): C992 - C1002.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Hsu, T. Nagayama, N. Koitabashi, M. Zhang, L. Zhou, D. Bedja, K. L. Gabrielson, J. D. Molkentin, D. A. Kass, and E. Takimoto
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway
Cardiovasc Res, February 1, 2009; 81(2): 301 - 309.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Ventura-Clapier, A. Garnier, and V. Veksler
Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha}
Cardiovasc Res, July 15, 2008; 79(2): 208 - 217.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Karatas, B. Hegner, L. J. de Windt, F. C. Luft, C. Schubert, V. Gross, Y. J. Akashi, D. Gurgen, U. Kintscher, A. C. da Costa Goncalves, et al.
Deoxycorticosterone Acetate-Salt Mice Exhibit Blood Pressure-Independent Sexual Dimorphism
Hypertension, April 1, 2008; 51(4): 1177 - 1183.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. V. Zima, D. J. Bare, G. A. Mignery, and L. A. Blatter
IP3-dependent nuclear Ca2+ signalling in the mammalian heart
J. Physiol., October 15, 2007; 584(2): 601 - 611.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Abbasi, J.-D. Lee, B. Su, X. Chen, J. L. Alcon, J. Yang, R. E. Kellems, and Y. Xia
Protein Kinase-mediated Regulation of Calcineurin through the Phosphorylation of Modulatory Calcineurin-interacting Protein 1
J. Biol. Chem., March 24, 2006; 281(12): 7717 - 7726.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Abbasi, B. Su, R. E. Kellems, J. Yang, and Y. Xia
The Essential Role of MEKK3 Signaling in Angiotensin II-induced Calcineurin/Nuclear Factor of Activated T-cells Activation
J. Biol. Chem., November 4, 2005; 280(44): 36737 - 36746.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. D. Barac, N. Zeevi-Levin, G. Yaniv, I. Reiter, F. Milman, M. Shilkrut, R. Coleman, Z. Abassi, and O. Binah
The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes
Cardiovasc Res, October 1, 2005; 68(1): 75 - 86.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. K. Wali, G. S. Wang, S. S. Gottlieb, L. Bellumkonda, R. Hansalia, E. Ramos, C. Drachenberg, J. Papadimitriou, M. A. Brisco, S. Blahut, et al.
Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1051 - 1060.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Burkard, J. Becher, C. Heindl, L. Neyses, K. Schuh, and O. Ritter
Targeted Proteolysis Sustains Calcineurin Activation
Circulation, March 1, 2005; 111(8): 1045 - 1053.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Heineke, H. Ruetten, C. Willenbockel, S. C. Gross, M. Naguib, A. Schaefer, T. Kempf, D. Hilfiker-Kleiner, P. Caroni, T. Kraft, et al.
Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc
PNAS, February 1, 2005; 102(5): 1655 - 1660.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C.-C. Lin, J.-L. Lin, C.-S. Lin, M.-C. Tsai, M.-J. Su, L.-P. Lai, and S. K. S. Huang
Activation of the Calcineurin-Nuclear Factor of Activated T-Cell Signal Transduction Pathway in Atrial Fibrillation
Chest, December 1, 2004; 126(6): 1926 - 1932.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
B. E.J. Teunissen, H. J. Jongsma, and M. F.A. Bierhuizen
Regulation of myocardial connexins during hypertrophic remodelling
Eur. Heart J., November 2, 2004; 25(22): 1979 - 1989.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Fiedler and K. C Wollert
Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes
Cardiovasc Res, August 15, 2004; 63(3): 450 - 457.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
V. P.M van Empel and L. J De Windt
Myocyte hypertrophy and apoptosis: a balancing act
Cardiovasc Res, August 15, 2004; 63(3): 487 - 499.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Tongers, B. Fiedler, D. Konig, T. Kempf, G. Klein, J. Heineke, T. Kraft, S. Gambaryan, S. M Lohmann, H. Drexler, et al.
Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes
Cardiovasc Res, August 15, 2004; 63(3): 545 - 552.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Pikkarainen, H. Tokola, R. Kerkela, and H. Ruskoaho
GATA transcription factors in the developing and adult heart
Cardiovasc Res, August 1, 2004; 63(2): 196 - 207.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Kawamura, K. Ono, T. Morimoto, M. Akao, E. Iwai-Kanai, H. Wada, N. Sowa, T. Kita, and K. Hasegawa
Endothelin-1-Dependent Nuclear Factor of Activated T Lymphocyte Signaling Associates With Transcriptional Coactivator p300 in the Activation of the B Cell Leukemia-2 Promoter in Cardiac Myocytes
Circ. Res., June 11, 2004; 94(11): 1492 - 1499.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. van Rooij, P. A. Doevendans, H. J.G.M. Crijns, S. Heeneman, D. J. Lips, M. van Bilsen, R. S. Williams, E. N. Olson, R. Bassel-Duby, B. A. Rothermel, et al.
MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction
Circ. Res., February 20, 2004; 94 (3): e18 - e26.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. Eefting, B. Rensing, J. Wigman, W. J. Pannekoek, W. M. Liu, M. J. Cramer, D. J Lips, and P. A Doevendans
Role of apoptosis in reperfusion injury
Cardiovasc Res, February 15, 2004; 61(3): 414 - 426.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Wang
Fill a Gab(1) in Cardiac Hypertrophy Signaling: Search a Missing Link Between gp130 and ERK5 in Hypertrophic Remodeling in Heart
Circ. Res., August 8, 2003; 93(3): 186 - 188.
[Full Text] [PDF]


Home page
Circ. Res.Home page
P. B. Bushdid, H. Osinska, R. R. Waclaw, J. D. Molkentin, and K. E. Yutzey
NFATc3 and NFATc4 Are Required for Cardiac Development and Mitochondrial Function
Circ. Res., June 27, 2003; 92(12): 1305 - 1313.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Wolk
Calcineurin, myocardial hypertrophy, and electrical remodeling
Cardiovasc Res, February 1, 2003; 57(2): 289 - 293.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. van Rooij, P. A. Doevendans, C. C. de Theije, F. A. Babiker, J. D. Molkentin, and L. J. De Windt
Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy
J. Biol. Chem., December 6, 2002; 277(50): 48617 - 48626.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.